|
|||||
|
|
Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin |
|
| Authors: | Raffit Hassan MD Christine Alewine MD PhD Idrees Mian MD Anna Spreafico MD PhD Lillian L. Siu MD FRCPC Carlos Gomez-Roca MD Jean-Pierre Delord MD PhD Antoine Italiano MD PhD Ulrik Lassen MD PhD Jean-Charles Soria MD PhD Rastilav Bahleda MD Anish Thomas MBBS MD Seth M. Steinberg PhD Cody J. Peer PhD William D. Figg PharmD Gerhard Niederfellner PhD Valérie Méresse Naegelen MD Ira Pastan PhD |
| Affiliation: | 1. Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland;2. Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland;3. Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada;4. Clinical Research Unit, IUCT-Oncopole, Toulouse, France;5. Department of Medicine, Bergonie Institute, Bordeaux, France Faculty of Medicine, University of Bordeaux, Bordeaux, France;6. Department of Oncology, Rigshospitalet, Copenhagen, Denmark Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark;7. Gustave Roussy Institute, Villejuif, France University of Paris–South, Orsay, France;8. Gustave Roussy Institute, Villejuif, France;9. Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland;10. Biostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland;11. Clinical Pharmacology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland;12. Clinical Pharmacology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland;13. Beoro Therapeutics GmbH, Seefeld, Germany;14. Pharma Research and Early Development, Roche Innovation Center, Basel, Switzerland |
| Abstract: | |
| Keywords: | immunotoxin LMB-100 mesothelin mesothelioma |